Monoclonal antibodies against COVID-19 

New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.

Support the development of new human monoclonal antibodies with potent activity against Omicron strains with licensing or direct investment.

The innovation

Human monoclonal antibodies with high binding affinity as well as the potent and broad neutralisation against SARS-CoV-2 variants Alpha, Beta, Gamma, Kappa, Delta and Omicron.

Market need

The Omicron variant is highly resistant against antibody-mediated neutralisation. Most monoclonal antibodies that were previously used to treat severe COVID-19 have lost efficacy against the Omicron variant.

Innovation status

The University of Melbourne human monoclonal antibodies are highly effective against SARS-CoV-2 variants in vitro and in animal models. The research team is working on generating a stable cell line for manufacturing a monoclonal antibody product suitable for Phase 1 clinical trial.



Download flyer for more information (PDF, 526 KB)